thiazolyl blue has been researched along with Bone Diseases, Metabolic in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baraldi, PG; Bianchini, E; Gambari, R; Lambertini, E; Penolazzi, L; Piva, R; Romagnoli, R | 1 |
1 other study(ies) available for thiazolyl blue and Bone Diseases, Metabolic
Article | Year |
---|---|
N-Arylpiperazine modified analogues of the P2X7 receptor KN-62 antagonist are potent inducers of apoptosis of human primary osteoclasts.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acid Phosphatase; Apoptosis; Bone and Bones; Bone Diseases, Metabolic; Caspase 3; Caspases; Cell Nucleus; Cells, Cultured; Enzyme Activation; Enzyme Inhibitors; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-6; Isoenzymes; Models, Chemical; NF-kappa B; Osteoblasts; Osteoclasts; Piperazines; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2X7; Tartrate-Resistant Acid Phosphatase; Tetrazolium Salts; Thiazoles; Time Factors | 2005 |